December 27, 2022
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 10, 2023. Mr. Read More
learn more
November 29, 2022
Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Optune is the first treatment for glioblastoma approved in Canada in over 12 years Novocure is actively working to secure reimbursement of Optune to make the therapy accessible for glioblastoma patients ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment… Read More
learn more
November 23, 2022
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 9:30 a.m. EST, as well as one-on-one… Read More
learn more
November 17, 2022
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Health economics and outcomes research showed post-Stupp therapeutic developments, including TTFields, significantly increase overall survival in a large commercially insured population The largest safety dataset to date of more than 23,000 patients reinforced that TTFields therapy is well-tolerated in patients with high-grade gliomas ROOT, Switzerland–(BUSINESS WIRE)–Novocure… Read More
learn more
November 15, 2022
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
Novocure chose Montreal because of its innovative culture, world-class universities and hospitals, access to top talent and quality of life ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global… Read More
learn more
November 11, 2022
Novocure Secures CE Mark for New Array
New arrays are lighter, thinner and more flexible than current commercial arrays and have the potential to optimize Tumor Treating Fields dose ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor… Read More
learn more
October 27, 2022
Novocure Reports Third Quarter 2022 Financial Results
Quarterly net revenues of $131 million with $52 million invested in research & development initiatives Entering a transformational period with multiple pivotal trial readouts anticipated in coming quarters ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a… Read More
learn more
October 21, 2022
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients Pre-clinical research shows the potential for improved tumor control when Tumor Treating Fields are used with PULSAR in glioblastoma, PARP inhibitors in ovarian cancer and PI3K inhibitors in non-small… Read More
learn more
October 20, 2022
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
A fast-growing body of research, both in vitro and in vivo, is converging to demonstrate the multiple inhibitory effects of Tumor Treating Fields on cancer growth The review article summarizes the known mechanisms of action of Tumor Treating Fields that have been reported by in vitro and in… Read More
learn more
October 20, 2022
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an emerging… Read More
learn more